Table 2.
Bevacizumab dose, steroid wean in the first 4 weeks and immunotherapy received after bevacizumab
| Bevacizumab Receiveda | Dexamethasone Doseb | Immunotherapy Received | ||||
|---|---|---|---|---|---|---|
| Patient | Dose | Cycles | Before | 4 weeks after | Type | Cycles |
| P01 | 5 mg/kg | 1 | 16 mg | N/A | Nil | 0 |
| P02 | 7.5 mg/kg Q3W | 2 | 8 mg | 0.5 mg | Ipilimumab | 1 |
| P03 | 7.5 mg/kg | 1 | 0 | 4 mg | Nil | 0 |
| P04 | 5 mg/kg Q3W | 4 | 8 mg | 3.2 mg | Ipilimumab | 1 |
| P05 | 5 mg/kg Q2W | 3 | 8 mg | 0.5 mg | Ipilimumab | 1 |
| P06 | 7.5 mg/kg Q3W | 3 | 6 mg | 2 mg | Ipilimumab | 2 |
| P07 | 7.5 mg/kg Q3W | 5 | 0 | 0 | Ipilimumab | 2 |
| P08 | 5 mg/kg Q2W | 4 | 2 mg | 0 | Pembrolizumab | 10 |
| P09 | 7.5 mg/kg Q2W x5 then Q3W x4 | 9 | 16 mg | 4 mg | Pembrolizumab | 5 |
| P10 | 7.5 mg/kg Q3‐4 W | 7 | 4 mg | 0 mg | Pembrolizumab | 10 |
| P11 | 7.5 mg/kg Q3W | 4 | 1 mg | 1 mg | Ipilimumab | 4 |
| P12 | 7.5 mg/kg Q2W | 5 | 0 | 0 | Ipilimumab | 2 |
a
Two patients received bevacizumab again later in the course of their disease for recurrence of neurological symptoms and radiological edema with good effect without concomitant use of steroids (data not shown).
b
Other corticosteroids converted to dexamethasone dose equivalent. Physiological replacement of steroids for treatment of cortisol insufficiency has been recorded as 0 mg.